Table 1.
Total | TBU | Non-TBU | P Value | |
---|---|---|---|---|
No. (%) | 79 (100%) | 49 (62%) | 30 (38%) | |
Presumed: 41 (84%) | ||||
Confirmed: 8 (16%) | ||||
Age (years) | 40.1 ± 12.2 | 41.8 ± 13.4 | 37.5 ± 9.7 | 0.135a |
Male sex | 25 (32) | 9 (18) | 16 (53) | 0.001 b |
HIV positive (n = 78) | 30 (38) | 12 (24) | 18 (62) | 0.001 b |
CD4+ cell count/L in HIV-positive cases (n = 28) | 171 (121–294) | 233 (155–473) | 137 (105–278) | 0.078c |
Laterality | 0.670b | |||
Unilateral | 19 (24) | 11 (22) | 8 (27) | |
Bilateral | 60 (76) | 38 (78) | 22 (73) | |
Analyzed eye | ||||
Right | 37 (47) | 17 (35) | 20 (67) | |
Left | 42 (53) | 32 (65) | 10 (33) | |
Anterior chamber/vitreous tap | ||||
Anterior chamber | 43 (54) | 28 (57) | 15 (50) | |
Vitreous | 36 (46) | 21 (43) | 15 (50) | |
TB contact | 14 (18) | 7 (14) | 7 (23) | 0.307b |
BCG vaccination at birth (n = 78) | 66 (85) | 40 (83) | 26 (87) | 0.691b |
Two-sample t test.
χ2 test.
Wilcoxon rank-sum test. Values are number (%), mean ± standard deviation, or median (interquartile range). Boldface entries indicate statistical significance. BCG, Bacille Calmette-Guerin